Phaseline

Companies › Arcutis Biotherapeutics

Arcutis Biotherapeutics: clinical trials, targets and expected readouts

2 active drug programs in 13 registered trials: 8 Phase 2, 2 Phase 1, 2 Phase 3, 1 Phase 4; Immunology, Oncology, Other, Psychiatry; next expected readout Apr 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Roflumilast
Phosphodiesterase 4 inhibitor
PDE4A, PDE4D, PDE4B, PDE4CPhase 3Atopic Dermatitis; Chronic Plaque Psoriasis; Depressive Disorder, Major; Fragile X Syndrome …Apr 2028
ARQ-234–Phase 1Atopic Dermatitis (AD)Apr 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05418049RoflumilastPhase 2Fragile X SyndromeOtherOct 2025
NCT07233291RoflumilastPhase 2Psoriasis (PsO)ImmunologyFeb 2026
NCT07105254RoflumilastPhase 2Non-segmental VitiligoImmunologyMay 2026
NCT07297602RoflumilastPhase 2Atopic DermatitisImmunologyMay 2026
NCT07632846RoflumilastPhase 2Rheumatoid ArthritisImmunologyDec 2026
NCT06860958RoflumilastPhase 3Depressive Disorder, MajorPsychiatryMar 2027
NCT06977711RoflumilastPhase 1Diffuse Large B-cell LymphomaOncologyApr 2027
NCT07566351RoflumilastPhase 2Rheumatoid ArthritisImmunologyJun 2027
NCT07725822RoflumilastPhase 4Chronic Plaque PsoriasisImmunologyJul 2027
NCT07689188RoflumilastPhase 2Hidradenitis Suppurativa (HS)ImmunologyMar 2028
NCT07453602ARQ-234Phase 1Atopic Dermatitis (AD)ImmunologyApr 2028
NCT07916480RoflumilastPhase 3Atopic DermatitisImmunologyApr 2028
NCT07263230RoflumilastPhase 2Hidradenitis Suppurativa (HS)ImmunologyAug 2028

From the company's SEC filings

Cash and short-term investments of $259m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Specialist investors

Held by 7 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PDE4A (1) PDE4D (1) PDE4B (1) PDE4C (1)

Companies with the same targets

Amgen MediciNova Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA Ganzhou Hemay Pharmaceutical Merck & Co. (MSD) Integrative Skin Science and Research Shionogi Tetra Discovery Partners

Companies built like this

Ganzhou Hemay Pharmaceutical Palisade Bio Integrative Skin Science and Research BioCryst Pharmaceuticals Pacira Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.